HARP News and Press, Harpoon Therapeutics Inc. From 02/27/23

The following slide deck was published by Harpoon Therapeutics, Inc. in conjunction with this event. For further details see: Harpoon Therapeutics (HARP) Presents at SVB Securities Global Biopharma Conference 2023

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will present at the virtual SVB Securities Global Biopharma Conference. The corporat...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If finding  undervalued stocks  is good, then finding undervalued  penny stocks  is even better. That’s because, with penny stocks, investors’ capital appreciation upside potential is amplified...

FinancialBuzz.com’s latest The Buzz Show: Featuing Our Corporate News Recap on “ Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial” Harpoon Therapeutics, Inc. (NASDAQ: HARP) , a clinical-stag...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Evgeny Karandaev/ShutterStock.com Reborn Coffee (NASDAQ: REBN ) stock is heating up on Monday as investors take note of the California coffee company’s shares. With that comes heavy trading of REB...

Nano cap biotech Harpoon Therapeutics ( NASDAQ: HARP ) added ~122% in the morning hours Monday after the company disclosed updated interim data from its Phase 1 clinical trial for investigational cancer therapy HPN217 in relapsed/refractory multiple myeloma (RRMM). The company sai...

Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma 77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses were durable, with many patients ...

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review updated interim results of its Phase 1 HPN...

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare ...

Harpoon Therapeutics press release ( NASDAQ: HARP ): Q3 GAAP EPS of -$0.35 beats by $0.20 . Revenue of $13.6M (+203.6% Y/Y) beats by $7.25M . Harpoon ended the third quarter of 2022 with $66.1M in cash, cash equivalents and marketable securities, compared to $1...